- Home
- AUUD vs RDHL Comparison
AUUD vs RDHL Comparison
Compare AUUD & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUUD
- RDHL
- Stock Information
- Founded
- AUUD 2012
- RDHL 2009
- Country
- AUUD United States
- RDHL Israel
- Employees
- AUUD N/A
- RDHL N/A
- Industry
- AUUD Computer Software: Prepackaged Software
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- AUUD Technology
- RDHL Health Care
- Exchange
- AUUD Nasdaq
- RDHL Nasdaq
- Market Cap
- AUUD 4.1M
- RDHL 3.9M
- IPO Year
- AUUD 2021
- RDHL N/A
- Fundamental
- Price
- AUUD $0.94
- RDHL $1.09
- Analyst Decision
- AUUD
- RDHL
- Analyst Count
- AUUD 0
- RDHL 0
- Target Price
- AUUD N/A
- RDHL N/A
- AVG Volume (30 Days)
- AUUD 71.0K
- RDHL 1.5M
- Earning Date
- AUUD 11-06-2025
- RDHL 09-05-2025
- Dividend Yield
- AUUD N/A
- RDHL N/A
- EPS Growth
- AUUD N/A
- RDHL N/A
- EPS
- AUUD N/A
- RDHL N/A
- Revenue
- AUUD N/A
- RDHL $9,550,000.00
- Revenue This Year
- AUUD N/A
- RDHL $381.91
- Revenue Next Year
- AUUD N/A
- RDHL N/A
- P/E Ratio
- AUUD N/A
- RDHL N/A
- Revenue Growth
- AUUD N/A
- RDHL 157.62
- 52 Week Low
- AUUD $0.84
- RDHL $1.01
- 52 Week High
- AUUD $14.60
- RDHL $8.75
- Technical
- Relative Strength Index (RSI)
- AUUD 29.89
- RDHL 39.31
- Support Level
- AUUD $0.84
- RDHL $1.01
- Resistance Level
- AUUD $1.10
- RDHL $1.07
- Average True Range (ATR)
- AUUD 0.08
- RDHL 0.05
- MACD
- AUUD 0.01
- RDHL 0.02
- Stochastic Oscillator
- AUUD 28.46
- RDHL 51.33
About AUUD Auddia Inc.
Auddia Inc is a technology company that is engaged in radio broadcasts and streaming audio content digitally. Its products includes Auddia App which is a subscription-based commercial-free AM/FM software application, and Vodacast an interactive podcasting platform and application. The company generates revenue through subscription fees from customers accessing the company's cloud-based computing services and advertisement services.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.